Modulation of beta-adrenergic receptor signaling in heart failure and longevity: targeting adenylyl cyclase type 5
- PMID: 20658186
- PMCID: PMC3655553
- DOI: 10.1007/s10741-010-9183-5
Modulation of beta-adrenergic receptor signaling in heart failure and longevity: targeting adenylyl cyclase type 5
Abstract
Despite remarkable advances in therapy, heart failure remains a leading cause of morbidity and mortality. Although enhanced beta-adrenergic receptor stimulation is part of normal physiologic adaptation to either the increase in physiologic demand or decrease in cardiac function, chronic beta-adrenergic stimulation has been associated with increased mortality and morbidity in both animal models and humans. For example, overexpression of cardiac Gsalpha or beta-adrenergic receptors in transgenic mice results in enhanced cardiac function in young animals, but with prolonged overstimulation of this pathway, cardiomyopathy develops in these mice as they age. Similarly, chronic sympathomimetic amine therapy increases morbidity and mortality in patients with heart failure. Conversely, the use of beta-blockade has proven to be of benefit and is currently part of the standard of care for heart failure. It is conceivable that interrupting distal mechanisms in the beta-adrenergic receptor-G protein-adenylyl cyclase pathway may also provide targets for future therapeutic modalities for heart failure. Interestingly, there are two major isoforms of adenylyl cyclase (AC) in the heart (type 5 and type 6), which may exert opposite effects on the heart, i.e., cardiac overexpression of AC6 appears to be protective, whereas disruption of type 5 AC prolongs longevity and protects against cardiac stress. The goal of this review is to summarize the paradigm shift in the treatment of heart failure over the past 50 years from administering sympathomimetic amine agonists to administering beta-adrenergic receptor antagonists, and to explore the basis for a novel therapy of inhibiting type 5 AC.
Figures






Similar articles
-
Beta-adrenergic receptor-G protein-adenylyl cyclase signal transduction in the failing heart.Am J Cardiol. 1999 Jun 17;83(12A):80H-85H. doi: 10.1016/s0002-9149(99)00266-0. Am J Cardiol. 1999. PMID: 10750593 Review.
-
Cardiac adenylyl cyclase overexpression precipitates and aggravates age-related myocardial dysfunction.Cardiovasc Res. 2019 Oct 1;115(12):1778-1790. doi: 10.1093/cvr/cvy306. Cardiovasc Res. 2019. PMID: 30605506 Free PMC article.
-
New aspects for the treatment of cardiac diseases based on the diversity of functional controls on cardiac muscles: effects of targeted disruption of the type 5 adenylyl cyclase gene.J Pharmacol Sci. 2009 Mar;109(3):354-9. doi: 10.1254/jphs.08r26fm. Epub 2009 Mar 7. J Pharmacol Sci. 2009. PMID: 19270422 Review.
-
Overexpression of adenylyl cyclase type 5 (AC5) confers a proarrhythmic substrate to the heart.Am J Physiol Heart Circ Physiol. 2015 Feb 1;308(3):H240-9. doi: 10.1152/ajpheart.00630.2014. Epub 2014 Dec 5. Am J Physiol Heart Circ Physiol. 2015. PMID: 25485900 Free PMC article.
-
Adenylyl cyclase type VI increases Akt activity and phospholamban phosphorylation in cardiac myocytes.J Biol Chem. 2008 Nov 28;283(48):33527-35. doi: 10.1074/jbc.M805825200. Epub 2008 Oct 5. J Biol Chem. 2008. PMID: 18838385 Free PMC article.
Cited by
-
Similarly potent inhibition of adenylyl cyclase by P-site inhibitors in hearts from wild type and AC5 knockout mice.PLoS One. 2013 Jul 1;8(7):e68009. doi: 10.1371/journal.pone.0068009. Print 2013. PLoS One. 2013. PMID: 23840883 Free PMC article.
-
Adrenergic signaling in heart failure and cardiovascular aging.Maturitas. 2016 Nov;93:65-72. doi: 10.1016/j.maturitas.2016.03.022. Epub 2016 Mar 26. Maturitas. 2016. PMID: 27062709 Free PMC article. Review.
-
Neurohormonal Effects of Intravenous Dopamine in Patients with Acute Heart Failure.J Clin Med. 2024 Sep 24;13(19):5667. doi: 10.3390/jcm13195667. J Clin Med. 2024. PMID: 39407727 Free PMC article.
-
Age Does Not Affect Metoprolol's Effect on Perioperative Outcomes (From the POISE Database).Anesth Analg. 2018 Apr;126(4):1150-1157. doi: 10.1213/ANE.0000000000002804. Anesth Analg. 2018. PMID: 29369093 Free PMC article.
-
β1-Adrenergic receptor blockade extends the life span of Drosophila and long-lived mice.Age (Dordr). 2013 Dec;35(6):2099-109. doi: 10.1007/s11357-012-9498-3. Epub 2013 Jan 15. Age (Dordr). 2013. PMID: 23314750 Free PMC article.
References
-
- Goldberg LI, et al. The direct effects of norepinephrine, epinephrine, and methoxamine on myocardial contractile force in man. Circulation. 1960;22:1125–32. - PubMed
-
- Gazes PC, Goldberg LI, Darby TD. Heart force effects of sympathomimetic amines as a basis for their use in shock accompanying myocardial infarction. Circulation. 1953;8(6):883–92. - PubMed
-
- Cotten MD, Pincus S. Comparative effects of a wide range of doses of L-epinephrine and of L-norepinephrine on the contractile force of the heart in situ. J Pharmacol Exp Ther. 1955;114(1):110–8. - PubMed
-
- Chidsey CA, et al. Myocardial Norepinephrine Concentration in Man. Effects of Reserpine and of Congestive Heart Failure. N Engl J Med. 1963;269:653–8. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- T32 HL069752-09/HL/NHLBI NIH HHS/United States
- HL069752/HL/NHLBI NIH HHS/United States
- R01 AG028854/AG/NIA NIH HHS/United States
- HL069020/HL/NHLBI NIH HHS/United States
- R01 AG023137-05/AG/NIA NIH HHS/United States
- P01 HL069020-09/HL/NHLBI NIH HHS/United States
- R01 HL065183-04/HL/NHLBI NIH HHS/United States
- P01 HL059139-10/HL/NHLBI NIH HHS/United States
- R01 AG023137/AG/NIA NIH HHS/United States
- R01 HL102472/HL/NHLBI NIH HHS/United States
- HL095888/HL/NHLBI NIH HHS/United States
- R01 HL093481-04/HL/NHLBI NIH HHS/United States
- R37 HL033107/HL/NHLBI NIH HHS/United States
- R01 AG014121-10/AG/NIA NIH HHS/United States
- T32 HL069752-08/HL/NHLBI NIH HHS/United States
- P01 AG027211/AG/NIA NIH HHS/United States
- T32 HL069752/HL/NHLBI NIH HHS/United States
- R01 HL095888-02/HL/NHLBI NIH HHS/United States
- R01 HL095888/HL/NHLBI NIH HHS/United States
- P20 HL101420/HL/NHLBI NIH HHS/United States
- R01 HL033107-27/HL/NHLBI NIH HHS/United States
- R01 HL033107/HL/NHLBI NIH HHS/United States
- R37 HL033107-17/HL/NHLBI NIH HHS/United States
- R01 AG014121-11/AG/NIA NIH HHS/United States
- T32 HL069752-07/HL/NHLBI NIH HHS/United States
- AG027211/AG/NIA NIH HHS/United States
- R01 AG028854-01/AG/NIA NIH HHS/United States
- HL102472/HL/NHLBI NIH HHS/United States
- HL093481/HL/NHLBI NIH HHS/United States
- R37 HL033107-18/HL/NHLBI NIH HHS/United States
- R01 HL095888-03/HL/NHLBI NIH HHS/United States
- P20 HL101420-02/HL/NHLBI NIH HHS/United States
- P01 HL069020/HL/NHLBI NIH HHS/United States
- R01 HL095888-04/HL/NHLBI NIH HHS/United States
- R01 HL102472-02/HL/NHLBI NIH HHS/United States
- R01 HL093481/HL/NHLBI NIH HHS/United States
- P01 HL059139/HL/NHLBI NIH HHS/United States
- P01 HL069020-10/HL/NHLBI NIH HHS/United States
- P01 AG027211-05/AG/NIA NIH HHS/United States
- HL101420/HL/NHLBI NIH HHS/United States
- HL033107/HL/NHLBI NIH HHS/United States
- P01 HL059139-09/HL/NHLBI NIH HHS/United States
- R01 AG014121/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous